Windlas Biotech Limited IPO
Mainboard₹13,800 / 30 Shares
Windlas Biotech Limited IPO Details
The Windlas Biotech Limited IPO price band is set between ₹448-460 per equity share, with a face value of ₹5 per share. The issue is managed by Link Intime India Private Limited, and the equity shares are proposed to be listed on the Mainboard.
The IPO date for subscription opens on 4 Aug, 2021 and closes on 6 Aug, 2021. Investors can check the allotment status on 11 Aug, 2021, while the listing date is tentatively scheduled for 16 Aug, 2021.
The total issue size is ₹401.53 Crores Total : ₹ 165 Crore Fresh + 236.53 Crore OFS of 51,42,067 Shares, aggregating up to . Stay tuned for the latest Windlas Biotech Limited IPO review and GMP updates.
Windlas Biotech Limited IPO Review, Rating & Analysis
Windlas Biotech Limited IPO Review
NO REVIEWWindlas Biotech Limited IPO Rating
Windlas Biotech Limited IPO Highlights
IPO Date
Aug 4, 2021 - Aug 6, 2021
Listing Date
16 Aug, 2021
Face Value
₹5 Per Equity Share
Price Band
₹448-460 per equity share
Lot Size
-
Fresh Issue
Shares
Offer for Sale
-
Listing At
BSE, NSE
Windlas Biotech Limited IPO Lot Size
The minimum market lot for Windlas Biotech Limited IPO is 30 shares with an application amount of ₹13,800. Retail investors can apply for up to 14 lots. The table below details the minimum and maximum investment limits for Retail and HNI investors.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 30 | ₹13,800 |
| Retail (Max) | 14 | 420 | ₹1,93,200 |
| S-HNI (Min) | 15 | 450 | ₹2,07,000 |
| S-HNI (Max) | 72 | 2160 | ₹9,93,600 |
| B-HNI (Min) | 73 | 2190 | ₹10,07,400 |
Windlas Biotech Limited IPO Timeline
Issue Price
₹448-460 per equity shareFace Value
₹5 Per Equity ShareListing at Group
BSE, NSERegistrar
Link Intime India Private LimitedLead Manager
SBI Capital Markets Limited, DAM Capital Advisors Limited, IIFL Securities LimitedIssue Size
₹401.53 Crores Total : ₹ 165 Crore Fresh + 236.53 Crore OFS of 51,42,067 SharesWindlas Biotech Limited IPO Financial Information
| Period Ended | Assets | Revenue | Profit After Tax | Net Worth | Reserves and Surplus | Total Borrowing |
|---|---|---|---|---|---|---|
| 31 Mar 21 | 296.12 | 430.69 | 15.57 | - | - | - |
| 31 Mar 20 | 338.48 | 331.33 | 16.21 | - | - | - |
| 31 Mar 19 | 198.18 | 311.52 | 63.82 | - | - | - |
| 31 Mar 18 | 298.88 | 356.57 | 11.19 | - | - | - |
All values are in ₹ Cr.
Promoters & Share Holding
Promoter(s) Name
- Ashok Kumar Windlass
- Hitesh Windlass
- Manoj Kumar Windlass
- AKW WBL Family Pvt Trust
| Share Holding Pre Issue | Share Holding Post Issue |
|---|---|
| 78% | 65.16% |
About Company
Windlas Biotech Ltd is one of the leading companies in the pharmaceutical formulations contract development and manufacturing organizations (CDMO) segment in India. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
It further sells its own branded products in the trade generics and OTC markets. Currently, the focus of the company is to launch complex generic products in the chronic therapeutic category related to lifestyle-related disorders. The business operates in 3 verticals; 1. CDMO Products and services, 2. Domestic trade generics and Over-the-counter (OTC) market (nutraceutical and health supplement products), and 3. Export.
Leading pharma companies i.e. Pfizer Ltd, Sanofi India Ltd, Cadila Healthcare Ltd, Emcure Pharmaceuticals Ltd, Eris Lifesciences Ltd, Intas Pharmaceuticals Ltd, and Systopic Laboratories Private Limited are some of the marquee customers of Windlas Biotech. Its manufacturing facility is located at Dehradun with an installed operating capacity of 7,063.83 million tablets/ capsules, 54.46 million pouch/ sachet, and 61.08 million liquid bottles.
Windlas Biotech Limited IPO Subscription Details
| As on | QIB | NII bNII sNII | Retail | Total |
|---|---|---|---|---|
| Shares Offered / Reserved | 17,45,804 | 13,09,354 | 30,55,159 | 61,10,317 |
Day 1 -04-08-21 05:00 PM | 0.00 x | 0.34 | 6.22 x | 3.18 x |
Day 2 -05-08-21 05:00 PM | 0.04 x | 1.11 | 13.40 x | 7.00 x |
Day 3 -06-08-21 08:00 PM | 24.10 x | 15.91 | 24.27 x | 22.47 x |
20.51 times
Frequently Asked Questions about Windlas Biotech Limited IPO IPO
When will Windlas Biotech Limited IPO open for subscription?
The Windlas Biotech Limited IPO opens on 4 Aug, 2021 and closes on 6 Aug, 2021.
What is the investors portion for Windlas Biotech Limited IPO?
The investors' portion for QIB is 24.10 x, NII is 15.91, and Retail is 24.27 x.
How to apply for Windlas Biotech Limited IPO?
You can apply for Windlas Biotech Limited IPO via ASBA online through your bank account. You can also apply via UPI through stock brokers like Zerodha, Upstox, or Paytm Money.
What is the issue size of Windlas Biotech Limited IPO?
The issue size of Windlas Biotech Limited IPO is approx ₹₹401.53 Crores Total : ₹ 165 Crore Fresh + 236.53 Crore OFS of 51,42,067 Shares crores.
What is the price band of Windlas Biotech Limited IPO?
The price band for Windlas Biotech Limited IPO is ₹448 to ₹460 per equity share.
What is the lot size of Windlas Biotech Limited IPO?
The minimum bid (lot size) for Windlas Biotech Limited IPO is N/A shares with an investment of approx ₹13,800 .
What is the allotment date of Windlas Biotech Limited IPO?
The allotment date for Windlas Biotech Limited IPO is 11 Aug, 2021.
What is the listing date of Windlas Biotech Limited IPO?
The listing date for Windlas Biotech Limited IPO is expected to be 16 Aug, 2021.
What is the GMP of Windlas Biotech Limited IPO?
The latest Grey Market Premium (GMP) for Windlas Biotech Limited IPO is being updated regularly on IPOROCK.
Parth D.
Founder & Lead Analyst
Parth D. is a software engineer and financial analyst who brings a quantitative edge to IPO tracking. With deep expertise in algorithmic trading and financial tool development, he builds the technology that powers IPORock's real-time data engines. He has been tracking the Indian market since 2018.